Endo-TAGSS

Executive Summary

Endo-TAGSS is developing the Trans-Abdominal Gastric Surgical System (TAGSS), a novel percutaneous gastric access device designed to enable minimally invasive intragastric and abdominal procedures. The system consists of a single, small-diameter port placed like a pull-type PEG tube, allowing the use of standard laparoscopic instruments. This approach aims to overcome limitations of current therapeutic endoscopy and laparoscopy, which often require multiple ports or specialized equipment, by providing a stable, versatile access point for a range of gastrointestinal diseases. The potential benefits include reduced procedural trauma, shorter recovery times, and lower costs, while expanding the scope of minimally invasive interventions. The company is currently in the pre-clinical stage, focusing on device refinement and initial animal studies. If successful, TAGSS could bridge the gap between endoscopic and laparoscopic techniques, offering a simpler, more adaptable solution for procedures such as gastric tumor resection, obesity interventions, and abdominal wall repairs. The technology addresses a clear unmet need in minimally invasive surgery, but its success hinges on demonstrating safety and efficacy in preclinical models and ultimately in human trials. With a strong intellectual property position and a clear clinical pathway, Endo-TAGSS represents an early-stage opportunity with significant potential, albeit with typical pre-clinical risks.

Upcoming Catalysts (preview)

• Q4 2026Completion of animal feasibility study70% success
• Q1 2027Submission of FDA pre-submission (Q-sub) for guidance60% success
• Q4 2027First-in-human study initiation40% success